L'impact de la CAO/FAO sur la QVT: le cas de Marconi

Suite à l'implantation de la CAO/F AO dans la compagnie Marconi Canada, une mesure de l'impact du changement sur la qualité de vie au travail (QVT) a été réalisée auprès de 104 utilisateurs de la nouvelle technologie. La QVT dans cette étude est perçue dans son sens le plus large englobant les dimensions du travail en soi, des conditions de travail, de la santé et la sécurité au travail et du contexte organisationnel. L'approche retenue pour mesurer les impacts est subjectiviste et ceux-ci sont différenciés, s'il y a lieu, selon la catégorie occupationnelle, le taux d'utilisation de la nouvelle technologie et la formation reçue en CAO/FAO.After the implementation of a CAD/CAM system at Marconi Canada, the impact of this new technology on the quality of worklife (QWL) of 104 users was assessed. In this study, QWL was defîned to encompass the characteristics of the work itself, working conditions, health and safety, and the organizational context. Respondents were asked how the new technology had affected the quality of their work life; information was also gathered on occupation, rate of utilisation of CAD/CAM procedures, and training received on the new technology.The results showed that enriching job content, improving interpersonal relations, and enhancing participation, cooperation, and communication all contributed to improving QWL. In contrast, increased mental burden, noise, isolation, control problems, aspects of the physical move, and health issues contributed to decreases in QWL. A further analysis, using concepts based on job satisfaction, showed that the respondents accorded the most importance to changes intrinsic to their work, most notably job enrichment

Estimating the Power of Indirect Comparisons: A Simulation Study

Indirect comparisons are becoming increasingly popular for evaluating medical treatments that have not been compared head-to-head in randomized clinical trials (RCTs). While indirect methods have grown in popularity and acceptance, little is known about the fragility of confidence interval estimations and hypothesis testing relying on this method.We present the findings of a simulation study that examined the fragility of indirect confidence interval estimation and hypothesis testing relying on the adjusted indirect method.Our results suggest that, for the settings considered in this study, indirect confidence interval estimation suffers from under-coverage while indirect hypothesis testing suffers from low power in the presence of moderate to large between-study heterogeneity. In addition, the risk of overestimation is large when the indirect comparison of interest relies on just one trial for one of the two direct comparisons.Indirect comparisons typically suffer from low power. The risk of imprecision is increased when comparisons are unbalanced

Guidelines for Reporting Health Research: The EQUATOR Network's Survey of Guideline Authors

Iveta Simera and colleagues survey the authors of 37 guidelines on reporting health research

SYNTHESYS+ Virtual Access - Report on the Ideas Call (October to November 2019)

The SYNTHESYS consortium has been operational since 2004, and has facilitated physical access by individual researchers to European natural history collections through its Transnational Access programme (TA). For the first time, SYNTHESYS+ will be offering virtual access to collections through digitisation, with two calls for the programme, the first in 2020 and the second in 2021. The Virtual Access (VA) programme is not a direct digital parallel of Transnational Access - proposals for collections digitisation will be prioritised and carried out based on community demand, and data must be made openly available immediately. A key feature of Virtual Access is that, unlike TA, it does not select the researchers to whom access is provided. Because Virtual Access in this way is new to the community and to the collections-holding institutions, the SYNTHESYS+ consortium invited ideas through an Ideas Call, that opened on 7th October 2019 and closed on 22nd November 2019, in order to assess interest and to trial procedures. This report is intended to provide feedback to those who participated in the Ideas Call and to help all applicants to the first SYNTHESYS+Virtual Access Call that will be launched on 20th of February 2020.This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The attached file is the published pdf

Anarchism, individualism and communism: William Morris's critique of anarcho-communism

This collection of essays, showing how the boundaries between Marxism and anarchism have been more porous and fruitful than is conventionally recognised, charts a history of radical socialist collaborations from the late 19th ..

The value of health care – a matter of discussion in Germany

BACKGROUND: Interest in assessing the value of health-care services in Germany has considerably increased since the foundation of the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen, IQWiG (Institute for Quality and Efficiency in Health Care). The practical application of value assessment illustrates how problematic the process can be. In all decisions made for the provision of health care, data concerning the measurable dimensions (quantity and quality of efficacy and effectiveness, validity of the results and costs) flow into a complex and not yet standardized decision-making process concerning public financing. Some of these decisions are based on data of uncertain validity, unknown reproducibility and unclear appropriateness. DISCUSSION: In this paper we describe the theoretical aspects of value from psychological and economic viewpoints and discuss national and international approaches. Methodic details and difficulties in assessing the value of health-care services are analysed. A definition of the intangible value of health-care services will be proposed which contains only three factors: the absolute risk reduction (usually a measure of efficacy), the validity of the scientific papers examined and the type of the expected effectiveness (prevention of death and disability, restitution of well-being). The intangible value describes the additional benefit when comparing two possible actions, like treatment or observation only. CONCLUSION: The description of intangible value from the viewpoint of different stakeholders is a useful measure for subsequent steps (not discussed here) – the evaluation of costs and of patient benefit. A standardised, transparent, fair and democratic evaluation is essential for the definition of a basic benefit package

Harpgophytum procumbens for osteoarthritis and low back pain: A systematic review

BACKGROUND: The objective of this review is to determine the effectiveness of Harpagophytum procumbens preparations in the treatment of various forms of musculoskeletal pain. METHODS: Several databases and other sources were searched to identify randomized controlled trials, quasi-randomized controlled trials, and controlled clinical trials testing Harpagophytum preparations in adults suffering from pain due to osteoarthritis or low back pain. RESULTS: Given the clinical heterogeneity and insufficient data for statistical pooling, trials were described in a narrative way, taking into consideration methodological quality scores. Twelve trials were included with six investigating osteoarthritis (two were identical trials), four low back pain, and three mixed-pain conditions. CONCLUSIONS: There is limited evidence for an ethanolic Harpagophytum extract containing less than <30 mg harpagoside per day in the treatment of knee and hip osteoarthritis. There is moderate evidence of effectiveness for (1) the use of a Harpagophytum powder at 60 mg harpagoside in the treatment of osteoarthritis of the spine, hip and knee; (2) the use of an aqueous Harpagophytum extract at a daily dose of 100 mg harpagoside in the treatment of acute exacerbations of chronic non-specific low back pain; and (3) the use of an aqueous extract of Harpagophytum procumbens at 60 mg harpagoside being non-inferior to 12.5 mg rofecoxib per day for chronic non-specific low-back pain (NSLBP) in the short term. Strong evidence exists for the use of an aqueous Harpagophytum extract at a daily dose equivalent of 50 mg harpagoside in the treatment of acute exacerbations of chronic NSLBP